Adze Biotechnology Initiates Phase 1 Clinical Trial of Adze1.C, a Treatment for Metastatic Melanoma
Oncolytic Virus Platform Enters Clinical Trial for Metastatic Melanoma
Adze Biotechnology's Australian subsidiary, Adze Biotechnology Australia Pty Ltd, has commenced the Phase 1 clinical trial (NCT07086105) of Adze1.C for metastatic melanoma, based on technology exclusively licensed from the Mayo Clinic. Adze1.C is a conditionally replicative oncolytic adenovirus that is designed to directly infect and kill cancer cells while also stimulating the body's immune response. It is engineered to express CD40 ligand (CD40L). Unlike conventional chemotherapy or simple immunotherapies, Adze1.C exhibits a unique mechanism of action by locally expressing the CD40L gene in the tumor microenvironment, destroying cancer cells and recruiting immune cells, such as dendritic cells. This innovative approach aims to reshape the tumor microenvironment and enhance the efficacy of solid tumor treatments.
A New Treatment Option for Patients with Resistance to Existing Immunotherapies
This clinical trial is designed to evaluate Adze1.C in patients with advanced metastatic melanoma who have not responded to or have developed resistance to standard treatments, including immune checkpoint inhibitors. While the introduction of immune checkpoint inhibitors has revolutionized melanoma treatment, a significant number of patients still develop resistance, leading to limited treatment options. Researchers at The Queen Elizabeth Hospital, the lead research institution for this Phase 1 trial, aim to directly administer Adze1.C to the tumors of these resistant patients, leveraging the tumor antigens and danger signals released from dying cells to generate a synergistic effect with next-generation immunotherapies. This approach has the potential to extend the treatment options and improve outcomes for patients with previously untreatable melanoma.
A Well-Designed Clinical Trial to Assess Safety and Determine Optimal Dosage
This multi-center Phase 1 trial builds upon the promising preclinical data and focuses on evaluating the safety and tolerability of Adze1.C in humans. The trial utilizes a 3+3 dose-escalation design to monitor patients for adverse events and to determine the maximum tolerated dose (MTD). The safety data and initial pharmacokinetic data generated in this phase will serve as the foundation for future Phase 2 and Phase 3 clinical trials, increasing the likelihood of successful clinical development. The investment community anticipates that effective management of early drug-related adverse events will be a key factor in advancing to later stages of clinical development and eventual regulatory approval.
$15 Million in Funding and Increasing Value of Exclusive License Pipeline
Adze Biotechnology has entered into an exclusive licensing agreement with the Mayo Clinic for the global rights to the oncolytic adenovirus technology developed in the laboratory of Dr. Michael Barry. The company successfully raised $6.2 million in the first closing of its Series A financing and is on track to achieve its goal of raising a total of $15 million. As an early-stage biotechnology company, achieving this clinical milestone is a significant driver of corporate value and will position the company favorably for future collaborations or licensing agreements with large pharmaceutical companies.
The market for metastatic melanoma is currently estimated at $7.8 billion to $10.2 billion and is projected to grow at a rate of over 10% per year, reaching up to $30 billion by the mid-2030s. The initiation of the Phase 1 trial for Adze1.C is significant because it targets a population of patients with refractory melanoma who have failed to respond to existing immune checkpoint inhibitors, such as Merck's Keytruda and Bristol Myers Squibb's Opdivo, addressing a significant unmet medical need. In the short term, the collection of safety and maximum tolerated dose (MTD) data from the Australian multi-center clinical trial will be a critical milestone for advancing to the next stage of clinical development. In the long term, if the efficacy of the CD40 ligand (CD40L)-expressing, replication-competent adenovirus platform is demonstrated, it could serve as a catalyst for increased technology transfer and co-development deals in the next-generation oncolytic virus market, following in the footsteps of Amgen's Imlygic.
Source: ClinicalTrials.gov (api_ct)